Company / PP&E (Net)
Aclaris Therapeutics, Inc. PP&E (Net) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$761.0K
FY2025
5-year range
$761.0K / $1.6M
FY2021-FY2025
Trend
-24.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 9 years, ranging from $761,000 in FY2025 to $2M in FY2019.
Based on SEC 10-K filings.
$761,000 in FY2025 with a 5-year CAGR of -14.4%.
Declined from $2M to $761,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -11.5%
- 5-Year CAGR
- -14.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.4%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 24.5% year-over-year.
- Peak pp&e (net) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $761.0K | -24.5% |
| FY2024 | $1.0M | -37.8% |
| FY2023 | $1.6M | +47.4% |
| FY2022 | $1.1M | -17.7% |
| FY2021 | $1.3M | -19.3% |
| FY2020 | $1.7M | -33.0% |
| FY2019 | $2.5M | +8.0% |
| FY2018 | $2.3M | +5.9% |
| FY2017 | $2.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026